Wolverine Trading’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $884K | Sell |
6,300
-900
| -13% | -$122K | ﹤0.01% | 3025 |
|
|
2025
Q2 | $903K | Buy |
+7,200
| New | +$826K | ﹤0.01% | 2411 |
|
|
2025
Q1 | – | Sell |
-5,200
| Closed | -$713K | – | 5451 |
|
|
2024
Q4 | $713K | Buy |
+5,200
| New | +$643K | ﹤0.01% | 3010 |
|
|
2024
Q3 | – | Sell |
-5,600
| Closed | -$771K | – | 5188 |
|
|
2024
Q2 | $771K | Buy |
5,600
+1,800
| +47% | +$247K | ﹤0.01% | 2430 |
|
|
2024
Q1 | $524K | Buy |
+3,800
| New | +$519K | ﹤0.01% | 2798 |
|
|
2022
Q3 | – | Sell |
-7,900
| Closed | -$778K | – | 5068 |
|
|
2022
Q2 | $778K | Sell |
7,900
-7,000
| -47% | -$646K | ﹤0.01% | 2141 |
|
|
2022
Q1 | $1.38M | Buy |
14,900
+11,800
| +381% | +$1M | ﹤0.01% | 2118 |
|
|
2021
Q4 | $262K | Sell |
3,100
-7,500
| -71% | -$690K | ﹤0.01% | 4334 |
|
|
2021
Q3 | $1M | Buy |
10,600
+3,300
| +45% | +$312K | ﹤0.01% | 2984 |
|
|
2021
Q2 | $708K | Buy |
7,300
+2,000
| +38% | +$192K | ﹤0.01% | 3222 |
|
|
2021
Q1 | $500K | Sell |
5,300
-7,700
| -59% | -$807K | ﹤0.01% | 3698 |
|
|
2020
Q4 | $1.24M | Sell |
13,000
-12,400
| -49% | -$1.2M | ﹤0.01% | 2164 |
|
|
2020
Q3 | $2.48M | Sell |
25,400
-2,400
| -9% | -$278K | 0.01% | 1317 |
|
|
2020
Q2 | $3.49M | Buy |
27,800
+2,600
| +10% | +$287K | 0.01% | 1028 |
|
|
2020
Q1 | $2.31M | Sell |
25,200
-29,800
| -54% | -$2.92M | 0.01% | 1230 |
|
|
2019
Q4 | $5.89M | Buy |
+55,000
| New | +$5.76M | 0.01% | 979 |
|
|
2019
Q2 | – | Sell |
-69,900
| Closed | -$6.16M | – | 4890 |
|
|
2019
Q1 | $6.16M | Sell |
69,900
-4,100
| -6% | -$343K | 0.02% | 757 |
|
|
2018
Q4 | $5.06M | Buy |
74,000
+20,600
| +39% | +$1.97M | 0.01% | 802 |
|
|
2018
Q3 | $6.57M | Sell |
53,400
-1,600
| -3% | -$182K | 0.01% | 798 |
|
|
2018
Q2 | $4.56M | Hold |
55,000
| – | – | 0.01% | 943 |
|
|
2018
Q1 | $4.56M | Buy |
55,000
+39,600
| +257% | +$3.34M | 0.01% | 943 |
|
|
2017
Q4 | $1.2M | Buy |
15,400
+2,000
| +15% | +$136K | ﹤0.01% | 2022 |
|
|
2017
Q3 | $821K | Sell |
13,400
-9,800
| -42% | -$517K | ﹤0.01% | 2083 |
|
|
2017
Q2 | $1.07M | Buy |
+23,200
| New | +$1.13M | ﹤0.01% | 1687 |
|
|
2016
Q4 | – | Sell |
-25,000
| Closed | -$1.26M | – | 4891 |
|
|
2016
Q3 | $1.26M | Buy |
25,000
+4,600
| +23% | +$229K | 0.01% | 1652 |
|
|
2016
Q2 | $926K | Buy |
+20,400
| New | +$939K | 0.01% | 1663 |
|
Other funds holding NBIX
Wolverine Trading's NBIX Position: Q3 2024 in Review
Wolverine Trading sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 3,915 shares — an estimated $539K sold.
Wolverine Trading first reported a position in NBIX in Q4 2016 and held it in 12 quarters. The position peaked at $1.43M in Q3 2018. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.
- Wolverine Trading reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
- Wolverine Trading sold 3,915 Neurocrine Biosciences shares in Q3 2024, an estimated $539K.
- Wolverine Trading first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 12 quarters.
- Wolverine Trading's Neurocrine Biosciences position peaked at $1.43M in Q3 2018.
- 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.
Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.